Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC1102 for Prevention of HBV Recurrence After Liver Transplantation
NCT03519113Phase 3Unknown
- Sponsor
- GC Biopharma
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of GC5103 in hepatitis B (HBV), sponsored by GC Biopharma. Status: unknown.
02
Drugs
GC5103
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03519113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519113.